在HER2阳性乳腺癌中透瘤的淋巴细胞:潜在的影响和挑战

I Schlam1, S Loi2, R Salgado3

  • 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/ilanaschlam.

ESMO open
|January 18, 2025
PubMed
概括

流体瘤透淋巴细胞 (sTILs) 作为HER2阳性乳腺癌的生物标志物具有前途,可预测治疗反应和患者的存活率. 临床整合需要进一步的研究.